Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd indu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Jasielec, Jagoda K., Kubicki, Tadeusz, Raje, Noopur, Vij, Ravi, Reece, Donna, Berdeja, Jesus, Derman, Benjamin A., Rosenbaum, Cara A., Richardson, Paul, Gurbuxani, Sandeep, Major, Sarah, Wolfe, Brittany, Stefka, Andrew T., Stephens, Leonor, Tinari, Kathryn M., Hycner, Tyler, Rojek, Alexandra E., Dytfeld, Dominik, Griffith, Kent A., Zimmerman, Todd M., Jakubowiak, Andrzej J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7714092/
https://ncbi.nlm.nih.gov/pubmed/32735641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007522
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak